康聖環球(09960.HK)旗下公司斥逾2.2億人幣購武漢物業作辦公及研發
康聖環球(09960.HK)公佈,於今日(15日),由公司主席黃士昂持有96.29%權益的武漢康聖達醫學檢驗所,與賣方訂立物業轉讓協議,向對方購買位於中國湖北武漢市東湖新技術開發區高新大道666號光谷生物城生物創新園D2-1棟的建築物之1至7樓物業,總代價爲2.24億元人民幣。
該物業目前由集團租用作其總辦事處及中國主要營業地點,總建築面積爲2.28萬平方米。收購事項完成後,集團將會把該物業用作辦公、研發及企業孵化。
武漢康聖達醫學檢驗所基於可變權益實體結構,已將其財務業績作爲公司附屬的方式合併及入賬處理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.